

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Porter Regional Hospital 2. 85 E. U.S. Hwy 6 Valparaiso, IN 46383		In accordance with letter dated January 08, 2019. 3. License number: 13-17073-01 is amended in its entirety to read as follows:	4. Expiration Date: November 30, 2023 5. Docket No.: 030-12150 Reference No.:
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200 C. Any byproduct material permitted by 10 CFR 35.300 D. Iridium-192 permitted by 10 CFR 35.400 E. Iodine-125 permitted by 10 CFR 35.400	7. Chemical and/or physical form A. Any B. Any C. Any D. Sealed Sources (Best Medical International, Inc., Model 81-01) E. Sealed Sources (Bard Brachytherapy, Inc, Model STM 1251)	8. Maximum amount that licensee may possess at any one time under this license A. As Needed B. As Needed C. 2 curies total D. 2 curies total E. 2 curies total	9. Authorized use A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. B. For use in imaging and localization studies permitted by 10 CFR 35.200. C. For any use permitted by 10 CFR 35.300. D. For any manual brachytherapy procedure permitted by 10 CFR 35.400. E. For any manual brachytherapy procedure permitted by 10 CFR 35.400.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-17073-01Docket or Reference Number
030-12150

Amendment No. 53

- | | | | |
|---|--|--|--|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use |
| F. Yttrium-90 permitted by 10 CFR 35.1000 | F. Microspheres (SIR-Spheres AEA Technology QSA, Model Sirtex Medical Limited SIR-Spheres) | F. 2 curies total | F. For medical use as permitted by 10 CFR 35.1000 in a Sirtex Medical Limited brachytherapy afterloader delivery system. |

CONDITIONS

10. A. Licensed material may be used or stored at the licensee's facilities located at 85 E. U.S. Hwy 6, Valparaiso, Indiana 46383.
- B. Licensed material in Subitem Nos. 6.A. and 6.B. may be used or stored at the licensee's facilities located at Porter Physician Services LLC d/b/a Porter Physician Group, 2000 Roosevelt Rd., Valparaiso, Indiana 46383.
11. The Radiation Safety Officer (RSO) for this license is James M. Forde, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User(M.D.,D.O.,etc.)

Amjad Alkadri, M.D.

Keith Atassi, M.D.

Material and Use

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300, 10 CFR 35.1000 (limited to yttrium-90 as SIR-Spheres)

10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

13-17073-01

Docket or Reference Number

030-12150

Amendment No. 53

Authorized User(M.D.,D.O.,etc.)

Omar Barakat, M.D.

Maximo V. Bleza, D.O.

James M. Forde, M.D.

Steven L. Hossler, M.D.

Jeffrey M. Huth, M.D.

Akram Kholoki, M.D.

Esther Lee, M.D.

Vivek Mishra, M.D.

Jeffrey Jon Quackenbush, M.D.

Sandeep Sehgal, M.D.

Jay D. Shah, M.D.

Michael Wheat, M.D.

Material and Use

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 and the parenteral administration of any beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV),10 CFR 35.1000 (limited to yttrium-90 as SIR-Spheres)

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300

10 CFR 35.100,10 CFR 35.200

10 CFR 35.100,10 CFR 35.200

10 CFR 35.100,10 CFR 35.200

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 and the parenteral administration of any beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV),10 CFR 35.1000 (limited to yttrium-90 as SIR-Spheres)

10 CFR 35.300,10 CFR 35.400

10 CFR 35.200

10 CFR 35.100,10 CFR 35.200

10 CFR 35.200 ☆ ☆ ☆ ☆

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-17073-01

Amendment No. 53

Docket or Reference Number
030-12150

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated June 21, 2013 (ML13183A468)
- B. Letter dated August 4, 2015 (ML15224B609)
- C. Letter dated September 22, 2017 (ML17268A220)
- D. Letter dated June 12, 2018 (ML18166A327)
- E. Letter dated January 8, 2019 (ML19010A319)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: January 14, 2019By: Colleen Carol Casey
Colleen Carol Casey
Region 3